Shares of GSK fell to below $30 around the time of the demerger, but have since recovered to about $36. The 20% gain over 34 ...

According to the latest study from BCC Research, "Biologic Therapeutic Drugs: Technologies and Global Markets" is projected ...

"Driven by Rising Chronic Disease Burden and Breakthrough FDA Approvals, Biopharmaceutical Market Surges with Demand for Monoclonal Antibodies, Gene and Cell Therapies, and Innovative Vaccines" BOSTON ...